Fairvalue-Calculator Fairvalue-Calculator
EN DE

Taiwan Biomaterial Co (6649) Fair Value & Analysis

Healthcare · TW · Market cap 1.6B TWD

Price36.45 TWD
Fair Value28.06 TWD
Upside-23.0%
Quality95/100
Evidence: High Range 21.05 TWD – 35.08 TWD

Fair value as of: Jun 24, 2026

Analysis

Taiwan Biomaterial Co (6649) currently trades at 36.45 TWD, while our model-based Fair Value estimate is 28.06 TWD — implying the stock looks roughly 23.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It provides Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regeneration products for the treatment of early osteoarthritis; and CDMO. The company was founded in 1921 and is based in Zhubei, Taiwan.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Taiwan Biomaterial Co (6649) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 28.06 TWD versus a price of 36.45 TWD — about −23% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6649?
Our 21-model fair value for Taiwan Biomaterial Co is 28.06 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 36.45 TWD.
What is the quality score of 6649?
Taiwan Biomaterial Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.